

Nanostructured Immunosensor for Attomolar Detection of Cancer Biomarker Interleukin-8 Using Massively Labeled Superparamagnetic Particles**

Bernard S. Munge,* Amy L. Coffey, Jaimee M. Doucette, Brian K. Somba, Ruchika Malhotra, Vyomesh Patel, J. Silvio Gutkind, and James F. Rusling

Extremely sensitive and accurate clinical measurements of biomarker proteins for early detection and monitoring of cancer pose a formidable challenge. However, successful inexpensive devices for reliable on-the-spot cancer diagnosis promise to lead to improved therapeutic outcomes with lower cost, decreased patient stress, and new targeted therapies.^[1–3] Such devices will also provide tools for a better fundamental understanding of disease progression, and enable biomarker-based monitoring of therapy.^[4] Herein, we report an ultrasensitive immunosensor based on a glutathione-protected gold nanoparticle (GSH-AuNP) sensor surface. When combined with novel massively labeled paramagnetic particles for the electrochemical detection of cancer biomarker interleukin 8 (IL-8), we obtained an unprecedented detection limit (DL) of 1 fg mL⁻¹ (100 aM) for IL-8, the lowest protein level yet detected in serum. Accuracy was demonstrated by determining IL-8 in conditioned media from head and neck squamous cell carcinoma (HNSCC) cells.

Our DL is lower than that of any method reported to date for direct biomarker protein detection in serum. It is similar to that of a DNA barcode method that used PCR amplification to achieve a DL of 1 fg mL⁻¹ (30 aM) in goat serum.^[5] Alternatively, fluorescence-based immunoassays were used to detect IL-6, IL-8 (DL 10 fM),^[6] and prostate-specific antigen (PSA, DL 3 fM) in serum.^[7] Surface plasmon resonance (SPR) using nanobead amplification has been used to detect brain natriuretic peptide (DL 25 pg mL⁻¹)^[8] in plasma, while our

group used clustered superparamagnetic bead labels in SPR to detect PSA (DL 10 fg mL⁻¹) in serum.^[9] Other modern strategies include commercial immunobead-based assays for multiplexed protein detection (DL ≈ 10 pg mL⁻¹),^[3,10] a dendrimer/conducting-polymer array for IL-8 mRNA (DL ≈ 4 fM) and IL-8 (DL 7.4 pg mL⁻¹)^[11] in saliva, and nanowire nanotransistors with DLs of 0.9 pg mL⁻¹ for various proteins in serum.^[12]

Herein, we report a simple nanostructured amperometric sensor electrode coated with a dense film of GSH-AuNP with attached primary antibodies (Ab₁) that capture human IL-8 from the sample. When coupled to superparamagnetic beads massively loaded with about 500 000 horseradish peroxidase (HRP) labels and secondary antibodies (Ab₂), an ultralow DL and very high sensitivity were achieved in sandwich immunoassays for IL-8 in serum. The enzyme labels are activated using hydrogen peroxide and hydroquinone to develop a step-like catalytic amperometric signal proportional to the amount of IL-8 in the sample.

We chose IL-8 as a model analyte protein because it is elevated in blood during inflammation and in the presence of several types of cancers including HNSCC.^[13–15] Approximately 44 000 patients are diagnosed with HNSCC each year in the USA with about 11 000 cases resulting in death.^[16] This high mortality rate is due to the difficulty of monitoring biomarker proteins for early detection. Current diagnoses rely on visual identification of lesions, often resulting in detection of cancers at advanced stages when prognosis is poor.^[16] The average concentration of IL-8 in serum of a healthy individual is ≤ 13 pg mL⁻¹, compared to elevated levels of ≥ 20 pg mL⁻¹ in patients with HNSCC.^[17] This provides a challenging application, since reliable diagnoses and active monitoring of HNSCC during therapy requires that changes in both normal and elevated levels of IL-8 be measured accurately. Furthermore, ultrasensitive detection methods will facilitate detecting recurrent cancer, and also enable sample dilution that can minimize interferences if ultrahigh sensitivity is not required.

A single biomarker found at an elevated level, however, does not give sufficient diagnostic accuracy. For example, PSA, the most widely used serum biomarker for prostate cancer, has a positive predictive value of only around 75%.^[18] Recent studies have shown that nearly 100% predictive success can be achieved by measuring panels of four to ten biomarkers of a particular cancer.^[19–21] Thus, sensitive multi-protein arrays are needed for point-of-care detection and monitoring. The ultrasensitive immunosensor development

[*] Prof. B. S. Munge, A. L. Coffey, J. M. Doucette, B. K. Somba
Department of Chemistry, Salve Regina University
100 Ochre Point Avenue, Newport, RI 02840 (USA)
E-mail: bernard.munge@salve.edu

R. Malhotra, Prof. J. F. Rusling
Department of Chemistry, University of Connecticut
55 North Eagleville Road, Storrs, CT 06269 (USA)
and

Department of Cell Biology, University of Connecticut Health Center,
Farmington, CT 06232 (USA)

Dr. V. Patel, Dr. J. S. Gutkind
Oral and Pharyngeal Cancer Branch, NIDCR/NIH
Bethesda, MD 20892 (USA)

[**] This research was financially supported by the NCCR/NIH (grant P20RR016457) awarded to B.S.M. and in part by the NIEHS/NIH (US PHS grant ES013557) awarded to J.F.R. Manuscript preparation was supported in part by the Intramural Research Program of NIDCR/NIH.



Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201102941>.

for IL-8 reported herein serves as the starting point for electrochemical immunosensors for panels of biomarker proteins.

Previously, we reported a AuNP immunosensor for detection of IL-6 with a DL of 10 pg mL^{-1} in calf serum without using labeled magnetic particles.^[22] A DL of 0.5 pg mL^{-1} was achieved for PSA in serum using approximately $1 \mu\text{m}$ magnetic beads containing about 7500 HRP labels per nanoparticle.^[23] Alternatively, we used single-walled carbon nanotube (SWNT) immunosensors coupled to multilabeled HRP-carbon nanotube (CNT)-HRP-Ab₂ detection bioconjugates to obtain a DL of 0.5 pg mL^{-1} for IL-6^[24] and 4 pg mL^{-1} for PSA^[25] in serum. In another strategy we used $0.5 \mu\text{m}$ multilabeled polymeric beads, polybeads-HRP-Ab₂, to achieve a DL of 10 pg mL^{-1} for matrix metalloproteinase-3 (MMP-3)^[26] in calf serum. These studies revealed that high sensitivity can be facilitated by using nanostructured sensor surfaces that contain large amounts of capture antibody in combination with multilabel particle strategies.

To demonstrate a wide dynamic range, two protocols were used: one to measure ultralow ($\leq 500 \text{ fg mL}^{-1}$) levels of IL-8 and another for more elevated levels. The highly sensitive immunosensor is achieved by use of the 5 nm GSH-AuNP nanostructured sensor platform, coupled with $1.0 \mu\text{m}$ massively loaded superparamagnetic beads (Ab₂-MB-HRP) with ≥ 500000 HRP labels attached through avidin-biotin interaction. This approach provides a massive number of HRP labels per binding event, thus allowing extremely sensitive monitoring of any changes in serum concentration with a remarkably low DL of 1 fg mL^{-1} . This ultrahigh sensitivity and low DL is also enabled by the nanostructured AuNP platform, which provides a large surface area allowing dense Ab₁ coverage. For elevated-level assays, biotinylated Ab₂ bound to streptavidin-HRP giving 14–16 labels per antigen used for detection gave a DL of 10 pg mL^{-1} (1.0 pM). We have used this strategy previously to detect IL-6 in serum.^[22]

Figure 1 shows these two immunosensor approaches: the Ab₂-HRP_(14–16) protocol (A) and the signal amplification strategy using multienzyme label Ab₂-MB-HRP (B) on GSH-AuNPs. Capture antibody, Ab₁, is conjugated to the GSH-AuNP electrode surface, blocked with 1% bovine serum albumin (BSA), and then washed with blocking buffer, phosphate-buffered saline (PBS) with 0.05% Tween 20, before addition of calf serum ($10 \mu\text{L}$) containing IL-8. The electrode is then washed and incubated with either Ab₂-HRP_(14–16) or Ab₂-MB-HRP. Finally, the electrode is washed and transferred to an electrochemical cell with PBS buffer (10 mL , pH 7.2) containing 1 mM hydroquinone mediator and then 0.4 mM H₂O₂ is injected to generate the amperometric signal.

AFM images of the immunosensor platform (Figure 1, inset) show a dense packing of the approximately 5 nm AuNPs on a flat mica substrate, consistent with previous reports.^[23] Our initial approach for elevated IL-8 antigen (Figure 1A) utilized the Ab₂-biotin-streptavidin-HRP_(14–16) label. Minimization of nonspecific binding (NSB) is critical to achieving the best sensitivity and DL,^[27,28] and BSA and Tween 20 were found to effectively block NSB. Furthermore,




Figure 1. Detection principles of AuNP immunosensors. The sensor surface after protein capture is shown on the left in the center. On the bottom left is a tapping-mode AFM image of a AuNP film that serves as the immunosensor platform. A) The immunosensor after treatment with biotinylated Ab₂ followed by streptavidin-modified HRP resulting in HRP-Ab₂ and providing 14–16 labels per binding event. B) The immunosensor after treatment with massively labeled Ab₂-MB-HRP particles to obtain amplification by providing around 500000 enzyme labels per binding event.

capture antibody (Ab₁; Figure S1A) and detection antibody (Ab₂; Figure S1B) concentrations were optimized (see the Supporting Information). The best analytical performance was obtained using $10 \mu\text{g mL}^{-1}$ for Ab₁ attachment and $0.05 \mu\text{g mL}^{-1}$ for Ab₂ (Figure S1). These optimal conditions were used to obtain a calibration curve with a sensitivity of $0.34 \text{ nA mL}^{-1} (\text{pg IL-8})^{-1} \text{ cm}^{-2}$ and a DL for the Ab₂-HRP_(14–16) of 10 pg mL^{-1} human IL-8 antigen (Figure 2). Figure 2A shows amperometric responses for IL-8 from 10 to 2000 pg mL^{-1} . The calibration curve (Figure 2B) shows a




Figure 2. Amperometric response for AuNP immunosensor incubated with IL-8 in undiluted newborn calf serum ($10 \mu\text{L}$) for 1.25 h then conventional anti-IL-8-biotin in 0.05% Tween 20 for 1.25 h followed by 30 min of incubation with streptavidin-modified HRP ($10 \mu\text{L}$) at 1:200 dilution. A) Sensor current (I) response at -0.3 V and 2000 rpm after placing electrodes in buffer containing 1 mM hydroquinone mediator, then injecting H₂O₂ to 0.4 mM to develop the signal. The control shown on the left indicates full immunoassay with serum containing 0 pg mL^{-1} IL-8. B) Corresponding calibration curve of IL-8. Errors bars show device-to-device standard deviations ($n=3$). $y=31.4+0.0543x$; $R=0.97817$.

linear relationship between concentration of IL-8 and change in the steady-state amperometric current. However, a more sensitive system is required to detect levels of IL-8 that fall below this DL.

Amperometric responses using $\text{Ab}_2\text{-MB-HRP}$ with increasing concentrations of IL-8 (Figure 3 A) range from 1 to 500 fg mL^{-1} . Figure 3 B presents a linear-logarithmic




Figure 3. Amperometric response for AuNP immunosensor incubated with IL-8 (concentration in fg mL^{-1} labeled on curves) in undiluted calf serum ($10 \mu\text{L}$) for 1.25 h. A) Current at -0.3 V and 2000 rpm using $\text{Ab}_2\text{-MB-HRP}$ bioconjugate. Control shown on left with AuNP immunosensor with 0 pg mL^{-1} IL-8. B) Corresponding calibration curve of IL-8 immunosensor using $\text{Ab}_2\text{-MB-HRP}$ bioconjugate. Errors bars represent device-to-device standard deviations. $y = 7.73 + 5.78 \log(x)$, $R = 0.93199$.

calibration curve with an extremely low DL of 1 fg mL^{-1} . The slight nonlinear behavior at higher concentrations could be related to clustering of the $\text{Ab}_2\text{-MB-HRP}$ conjugate.^[9] The 1 fg mL^{-1} DL is 10000-fold lower than that of our $\text{Ab}_2\text{-biotin-streptavidin-HRP}_{(14-16)}$ protocol and 30000-fold lower than that of the standard ELISA^[29] method.

At very low IL-8 concentrations ($1\text{--}50 \text{ fg mL}^{-1}$) the sensitivity is $1060 \text{ nA mL}(\text{fg IL-8})^{-1} \text{ cm}^{-2}$. The massively labeled $\text{Ab}_2\text{-MB-HRP}$ bioconjugate particle allowed for ultrahigh sensitivity by virtue of the large number of HRP labels, which corresponds to the concentration of IL-8 in a given sample through the amperometric response. To make the detection particles, biotinylated HRP and Ab_2 were bioconjugated to $1 \mu\text{m}$ streptavidin-coated magnetic beads with a reaction mixture having a 6800:1 HRP/ Ab_2 mole ratio. These multilabeled magnetic particles with hundreds of thousands of HRP labels were used in place of the conventional $\text{Ab}_2\text{-HRP}_{(14-16)}$ complex. The number of active HRP labels was estimated at 502700 per bead using the 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) HRP activity assay (see the Supporting Information, Figure S2). To reduce NSB in the amplified system, it was necessary to increase BSA in the blocking solution from 1 to 5% with the same amount of incubation time.

The sensitivity is six orders of magnitude better than that obtained with the $\text{Ab}_2\text{-HRP}_{(14-16)}$ protocol. The large number of labels on the $\text{Ab}_2\text{-MB-HRP}$ bioconjugate significantly increases sensitivity and lowers DL compared to $\text{Ab}_2\text{-HRP}_{(14-16)}$. This extremely high HRP label loading on the magnetic beads is achieved by taking advantage of interactions between the streptavidin-coated magnetic beads and biotinylated HRP

labels. Streptavidin-biotin has a very large affinity constant ($K_a = 10^{15} \text{ M}$) and has four biotin binding sites for each streptavidin molecule.^[30]

As a proof of concept to establish method accuracy, we then used the immunosensor to determine secreted levels of IL-8 in in-vitro cell preparations. Conditioned media from heterogeneous populations of six different cell lines were analyzed to test the validity of our immunosensor approach towards IL-8 detection in HNSCC.

Figure 4 A shows amperometric signals for different cell lines along with human IL-8 standards in serum at comparable levels. Most of the HNSCC cancer cell lines (HEp2,




Figure 4. Amperometric response for AuNP immunosensor incubated with IL-8 (concentration labeled on curves) or conditioned media containing IL-8 secreted by human squamous cells. Conditioned media samples from HNSCC cell lines (HEp2, HN13, OSCC3, Cal27), immortalized epidermal (HaCaT) and mucosal (NOKsi) squamous cells, and serum-free (SF) media were analyzed using biotinylated Ab_2 ($10 \mu\text{L}$, $0.05 \mu\text{g mL}^{-1}$) in 0.1% BSA in pH 7.2 PBS buffer and streptavidin-modified HRP ($10 \mu\text{L}$). A) Current at -0.3 V and 2000 rpm using hydroquinone mediator in PBS buffer, after injecting H_2O_2 to 0.4 mM. B) AuNP sensor results for conditioned media shown with results from ELISA of the samples.

HN13, OSCC3, Cal27) were found to contain high levels of IL-8, ranging from 612 to 1760 pg mL^{-1} , while HaCaT and NOKsi demonstrated low levels of the antigen, ranging from 46 to 99 pg mL^{-1} . Spontaneously immortalized HaCaT and NOKsi cells were essentially established from normal epidermal and oral mucosal tissues, respectively, and maintained normal phenotypic features. Samples were also analyzed using the standard ELISA method, and gave excellent correlations with our AuNP immunosensor (Figure 4 B). These results confirm the accuracy of this immunosensor for measurement of IL-8 in complex samples of a variety of cancer cell types.

In summary, we have reported a new electrochemical immunosensor protein detection method with ultrasensitive, selective, and reproducible measurement of IL-8. The streptavidin-modified magnetic bead amplification strategy gave a DL of 1.0 fg mL^{-1} , to our knowledge the lowest yet reported for a protein in serum. This DL is 30000-fold lower than that of the conventional ELISA and about 1000-fold lower than that of commercial bead-based protein assays.^[3,9] Accurate results were demonstrated for cell culture media samples representative of low cancer-free and high expression levels in cancer patients for a range of head and neck cancer cell lines. The strategy reported for these single-protein sensors has

great promise for extension to arrays for clinical cancer screening and therapy monitoring.

Experimental Section

Monoclonal antihuman IL-8 antibody, biotinylated antihuman IL-8 antibody, recombinant IL-8 in calf serum, and streptavidin–HRP were from R&D Systems, Inc. HaCaT and the oral cancer cell lines were cultured as previously described^[24] in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), at 37°C in 95% air/5% CO₂, and the immortalized NOKsi cells were grown in defined keratinocyte serum-free medium KGM with the provided growth supplements (Invitrogen). Conditioned media from the different cells were prepared by incubating cells at 60–70% confluence, for 48 h in DMEM or KGM without supplements. Harvested conditioned media were then filtered to remove cellular debris and the samples were divided into aliquots and stored at –70°C prior to analysis. Streptavidin-coated superparamagnetic beads were from Polyscience, Inc. Biotinylated HRP was from Invitrogen. HRP (molecular weight 44000 Da), lyophilized 99% BSA, Tween 20, methanol, acetic acid, sodium borohydride, gold(III) chloride trihydrate, poly(diallyldimethylammonium chloride) (PDDA; 20 wt.% in water), and L-glutathione were from Sigma–Aldrich. Immunoreagents were dissolved in PBS buffer (0.137 M NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.5 mM NaH₂PO₄; pH 7.2). N-Hydroxysulfosuccinimide (NHS) and 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) from Aldrich were dissolved in water immediately before use. A GSH–AuNP platform was assembled on the pyrolytic graphite (PG) tip of an electrode using a monolayer of PDDA. Capture antibody (Ab₁) was attached on the GSH–AuNP platform followed by IL-8 standards in serum and/or conditioned media samples. Then Ab₂–HRP^(14–16) was added for electrochemical detection of elevated levels of IL-8. Alternatively, massively loaded 1 μm magnetic beads (Ab₂–MB–HRP) with hundreds of thousands of HRP labels were used to detect ultralow levels of IL-8. Finally, the sensor was placed in an electrochemical cell containing PBS buffer (10 mL, pH 7.2) with 1 mM hydroquinone as a mediator. Amperometry was performed by rotating the disk at 2000 rpm and then injecting 0.4 mM H₂O₂ to generate the electrochemical signal. Details of GSH–AuNP platform fabrication, synthesis of Ab₂–MB–HRP bioconjugate, and the immunosensor protocol are provided in the Supporting Information.

Received: April 28, 2011

Published online: June 30, 2011

Keywords: cancer · electrochemistry · immunosensors · interleukin-8 · magnetic beads

- [1] U. Manne, R. G. Srivastava, S. Srivastava, *Drug Discovery Today* **2005**, *10*, 965–976.
- [2] S. M. Hanash, C. S. Baik, O. Kallioniemi, *Nat. Rev. Clin. Oncol.* **2011**, *8*, 142–150.
- [3] J. F. Rusling, C. V. Kumar, J. S. Gutkind, V. Patel, *Analyst* **2010**, *135*, 2496–2511.

- [4] M. S. Wilson, W. Y. Nie, *Anal. Chem.* **2006**, *78*, 6476–6483.
- [5] J. M. Nam, C. S. Thaxton, C. A. Mirkin, *Science* **2003**, *301*, 1884–1886.
- [6] T. Konry, R. B. Hayman, D. R. Walt, *Anal. Chem.* **2009**, *81*, 5777–5782.
- [7] D. Kim, W. L. Daniel, C. A. Mirkin, *Anal. Chem.* **2009**, *81*, 9183–9187.
- [8] Y. Teramura, Y. Arima, H. Iwata, *Anal. Biochem.* **2006**, *357*, 208–215.
- [9] S. Krishnan, V. Mani, D. Wasalathanthri, C. V. Kumar, J. F. Rusling, *Angew. Chem.* **2011**, *123*, 1207–1210; *Angew. Chem. Int. Ed.* **2011**, *50*, 1175–1178.
- [10] Luminex Corp., <http://luminexcorp.com/technology/index.html>.
- [11] F. Wei, P. Patel, W. Liao, K. Chaudhry, L. Zhang, M. Arellano-Garcia, S. Hu, D. Elashoff, H. Zhou, S. Shukla, F. Shah, C. Ho, D. T. Wong, *Clin. Cancer Res.* **2009**, *15*, 4446–4452.
- [12] G. Zheng, F. Patolsky, Y. Cui, W. Wang, C. Lieber, *Nat. Biotechnol.* **2005**, *23*, 1294–1301.
- [13] W. L. Bigbee, J. R. Grandis, J. M. Siegfried, *Clin. Cancer Res.* **2007**, *13*, 3107–3108.
- [14] A. N. Cohen, M. S. Veena, E. S. Srivatsan, M. B. Wang, *Arch. Otolaryngol. Head Neck Surg.* **2009**, *135*, 190–197.
- [15] R. F. Cohen, J. Contrino, J. D. Spiro, E. A. Mann, L. L. Chen, D. L. Kreutzer, *Arch. Otolaryngol. Head Neck Surg.* **1995**, *121*, 202–209.
- [16] A. Jemal, R. Siegel, J. Xu, E. Ward, *CA: Cancer J. Clin.* **2010**, *60*, 277–300.
- [17] A. S. Gokhalea, R. I. Haddad, L. A. Cavacinia, L. Wirth, L. Weeks, M. Hallar, J. Faucher, M. R. Posner, *Oral Oncol.* **2005**, *41*, 70–76.
- [18] H. Lilja, D. Ulmert, A. Vickers, *Nat. Rev. Cancer* **2008**, *8*, 268–278.
- [19] S. M. Hanash, S. J. Pitteri, V. M. Faca, *Nature* **2008**, *452*, 571–579.
- [20] E. V. Stevens, L. A. Liotta, E. C. Kohn, *Int. J. Gynecol. Cancer* **2003**, *13*, 133–139.
- [21] P. D. Wagner, M. Verma, S. Srivastava, *Ann. N. Y. Acad. Sci.* **2004**, *1022*, 9–16.
- [22] B. S. Munge, C. E. Krause, R. Malhotra, V. Patel, J. S. Gutkind, J. F. Rusling, *Electrochem. Commun.* **2009**, *11*, 1009–1012.
- [23] V. Mani, B. V. Chikkaveeraiah, V. Patel, J. S. Gutkind, J. F. Rusling, *ACS Nano* **2009**, *3*, 585–594.
- [24] R. Malhotra, V. Patel, P. J. Vaque, J. S. Gutkind, J. F. Rusling, *Anal. Chem.* **2010**, *82*, 3118–3123.
- [25] X. Yu, B. Munge, V. Patel, G. Jensen, A. Bhirde, J. D. Gong, S. N. Kim, J. Gillespie, J. S. Gutkind, F. Papadimitrakopoulos, J. F. Rusling, *J. Am. Chem. Soc.* **2006**, *128*, 11199–11205.
- [26] B. S. Munge, J. Fisher, L. N. Millord, C. E. Krause, R. S. Dowd, J. F. Rusling, *Analyst* **2010**, *135*, 1345–1350.
- [27] D. S. Wilson, S. Nock, *Angew. Chem.* **2003**, *115*, 510–517; *Angew. Chem. Int. Ed.* **2003**, *42*, 494–500.
- [28] A. M. Ward, J. W. F. Catto, F. C. Hamdy, *Ann. Clin. Biochem.* **2001**, *38*, 633–651.
- [29] <http://www.rndsystems.com/pdf/dy208.pdf>
- [30] E. P. Diamandis, T. K. Christopoulos, *Clin. Chem.* **1991**, *37*, 625–636.